{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-134097","form_type":"8-K/A","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.658811+00:00","generated_at":"2026-05-15T08:10:08.000043+00:00","sec_items":["9.01","2.01","1.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LeonaBio files amended 8-K on Sermonix license, provides ELAINE-3 cost and timeline update","bullets":["SEC granted waiver from providing Sermonix financial statements; license deal treated as business acquisition under Regulation S-X.","Sermonix reported ELAINE-3 cash expenditures of $14M (2023), $12M (2024), $5M (2025 through Dec 18).","LeonaBio expects $45M (2026) and $30M (2027) in ELAINE-3 cash spend; made ~$11M from Dec 18–31, 2025.","ELAINE-3 protocol amended to increase sample size from 500 to up to 600; enrollment completion targeted Q4 2026, topline data H2 2027.","License agreement grants LeonaBio exclusive rights to lasofoxifene for oncology outside Retained Territory."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-134097","json":"https://secwatch.observer/filing/0001193125-26-134097.json","markdown":"https://secwatch.observer/filing/0001193125-26-134097.md","text":"https://secwatch.observer/filing/0001193125-26-134097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526134097/0001193125-26-134097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526134097/lona-20251218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:10:08.000043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}